Estimating the cost of type 1 diabetes in Ireland. Issue 5 (4th January 2022)

• Record Type: Journal Article
• Authors: Sharma, Shikha; Gillespie, Paddy; Hobbins, Anna; Dinneen, Sean F.
• Is Part Of: Diabetic medicine. Volume 39:Issue 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-04
• Subjects: burden of disease -- complications -- cost -- cost‐of‐illness -- economics -- epidemiology -- prevalence -- treatment -- type 1 diabetes; Diabetes -- Periodicals; 616.462
• DOI: 10.1111/dme.14779
• Languages: English
• ISSNs: 0742-3071

Abstract

Abstract: Background: Type 1 diabetes is a chronic disease, which given its existing and projected prevalence, is likely to pose a significant economic burden, both in terms of directs costs to the healthcare system and indirect costs to society. We aimed to estimate the economic burden of type 1 diabetes in Ireland, which at present, is unknown. Methods: A cost of illness study was undertaken to estimate the cost of type 1 diabetes in Ireland for 2018. Data for prevalence, morbidity, mortality, healthcare resource use, absenteeism, and unit costs were obtained from national, and where necessary, international sources. Direct healthcare costs were estimated for primary care, outpatient, emergency and inpatient care, for associated complications, structured education programmes, insulin and related care. Additionally, indirect costs from lost earnings due to premature death and employee absenteeism were estimated. Results: Type 1 diabetes was estimated to cost €129 million in Ireland in 2018, with direct healthcare costs accounting for €81.5 million or 63% and indirect costs for €47.5 million or 37% of the total. On average, this amounted to €3994 per patient in direct healthcare costs and €2326 per patient in indirect costs. Conclusion: Type 1 diabetes is a leading public health problem. Our study is the first to assess the economic burden of type 1 diabetes in Ireland, and our results should be informative to policymakers tasked with prioritising healthcare and research funding resource allocation.